⚠ Scores are AI-generated estimates for informational purposes only — not investment advice. Data may be inaccurate or outdated. Do not make financial decisions based on this site. Full legal disclaimer →
⚠ Scores are AI-generated estimates for informational purposes only — not investment advice. Data may be inaccurate or outdated. Do not make financial decisions based on this site. Full legal disclaimer →
AI Exposure Analysis
Healthcare · Large Cap · Disruption threat: LOW
AstraZeneca continues to embed AI deeply into drug discovery, clinical trial design, and genomics pipelines, with partnerships spanning Benevolent AI, Recursion, and internal platforms like Evinova for digital health. No major new AI-specific revenue disclosures or structural shifts in the 2025 filing warrant a score change from the prior assessment.
AstraZeneca is a global biopharmaceutical company focused on oncology, cardiovascular, and respiratory therapeutics. With an overall AI score of 66/100, the company reflects a meaningful but still-developing AI integration profile, one characterized more by embedded research workflows than commercialized AI revenue streams. The score is anchored by strong R&D AI Investment (78/100) and Product AI Integration (72/100), reflecting AstraZeneca's use of AI across drug discovery, target identification, clinical trial optimization, and precision medicine via genomics pipelines. Partnerships with Benevolent AI and Recursion, alongside the internally developed Evinova digital health platform, demonstrate tangible strategic commitments. Internal AI Use (68/100) is solid, though AI Infrastructure (55/100) suggests room for deeper technical buildout. Revenue from AI (20/100) confirms that monetization of these capabilities remains nascent. The LOW disruption threat designation is appropriate for AstraZeneca's positioning. AI is functioning as an accelerant to existing pharmaceutical workflows rather than an existential competitive force, and the company's scale and pipeline depth provide a durable moat against near-term displacement. The primary opportunity lies in converting R&D efficiency gains into faster pipeline progression and reduced trial costs. Should Evinova scale successfully, it could eventually represent a distinct AI-driven revenue layer, a meaningful re-rating catalyst investors should monitor.
Full interactive analysis at RankVis.io